{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:06:48Z","timestamp":1792843608079,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s12022-024-09836-x","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T23:28:05Z","timestamp":1732318085000},"page":"293-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0469-2801","authenticated-orcid":false,"given":"Ozgur","family":"Mete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2625-0086","authenticated-orcid":false,"given":"Andr\u00e9e","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7413-4314","authenticated-orcid":false,"given":"Kasmintan A.","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-2502","authenticated-orcid":false,"given":"Omar","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5607-6368","authenticated-orcid":false,"given":"Houda","family":"Bahig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-3984","authenticated-orcid":false,"given":"Cheryl","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9289-482X","authenticated-orcid":false,"given":"Olfat Kamel","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2183-7208","authenticated-orcid":false,"given":"Bernard","family":"Lemieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8829-5979","authenticated-orcid":false,"given":"Eric","family":"Winquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4879-0147","authenticated-orcid":false,"given":"Jonn","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9317-3642","authenticated-orcid":false,"given":"Nicole","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8343-3068","authenticated-orcid":false,"given":"Shereen","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"key":"9836_CR1","unstructured":"WHO Classification of Tumours Editorial Board: Endocrine and Neuroendocrine tumours, vol. 8. 5th edn. (International Agency for Research on Cancer, Lyon, France, 2022) https:\/\/tumourclassification.iarc.who.int, 2022."},{"key":"9836_CR2","doi-asserted-by":"crossref","unstructured":"Christofer Juhlin C, Mete O, Baloch ZW. The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocrine-related cancer 30(2):e220293, 2023.","DOI":"10.1530\/ERC-22-0293"},{"key":"9836_CR3","doi-asserted-by":"crossref","unstructured":"Vissio E, Maletta F, Fissore J et al. External Validation of Three Available Grading Systems for Medullary Thyroid Carcinoma in a Single Institution Cohort. Endocr Pathol 33: 359-370, 2022.","DOI":"10.1007\/s12022-022-09719-z"},{"key":"9836_CR4","doi-asserted-by":"crossref","unstructured":"La Rosa S. Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future. Endocr Pathol 34: 79-97, 2023.","DOI":"10.1007\/s12022-023-09755-3"},{"key":"9836_CR5","doi-asserted-by":"crossref","unstructured":"Williams JF, Zhao M, Najdawi F et al. Grading of Medullary Thyroid Carcinoma: an Interobserver Reproducibility Study. Endocr Pathol 33: 371-377, 2022.","DOI":"10.1007\/s12022-022-09718-0"},{"key":"9836_CR6","doi-asserted-by":"crossref","unstructured":"Jung CK, Agarwal S, Hang JF, Lim DJ, Bychkov A, Mete O. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma. Endocr Pathol 34: 1-22, 2023.","DOI":"10.1007\/s12022-023-09753-5"},{"key":"9836_CR7","doi-asserted-by":"crossref","unstructured":"Brenner DR, Gillis J, Demers AA et al. Projected estimates of cancer in Canada in 2024. Cmaj 196: E615-e623, 2024.","DOI":"10.1503\/cmaj.240095"},{"key":"9836_CR8","unstructured":"Canadian Cancer Statistics 2023 https:\/\/cancer.ca\/en\/research\/cancer-statistics\/canadian-cancer-statistics (Last Accessed May 6, 2024), 2023."},{"key":"9836_CR9","doi-asserted-by":"crossref","unstructured":"Cameselle-Teijeiro JM, Mete O, Asa SL, LiVolsi V. Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates. Endocr Pathol 32: 77-101, 2021.","DOI":"10.1007\/s12022-020-09661-y"},{"key":"9836_CR10","doi-asserted-by":"crossref","unstructured":"Boucai L, Zafereo M, Cabanillas ME. Thyroid Cancer: A Review. JAMA 331: 425-435, 2024.","DOI":"10.1001\/jama.2023.26348"},{"key":"9836_CR11","doi-asserted-by":"crossref","unstructured":"Tao Z, Deng X, Guo B, Ding Z, Fan Y. Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000\u20132020: a population-based retrospective cohort study. Endocrine-related cancer 31, 2024.","DOI":"10.1530\/ERC-23-0319"},{"key":"9836_CR12","doi-asserted-by":"crossref","unstructured":"Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. Jama 317: 1338-1348, 2017.","DOI":"10.1001\/jama.2017.2719"},{"key":"9836_CR13","unstructured":"Lin B, Ma H, Ma M et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Transl Res 11: 5888-5896, 2019."},{"key":"9836_CR14","doi-asserted-by":"crossref","unstructured":"Maniakas A, Dadu R, Busaidy NL et al. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncology 6: 1397-1404, 2020.","DOI":"10.1001\/jamaoncol.2020.3362"},{"key":"9836_CR15","doi-asserted-by":"crossref","unstructured":"Horgan D, F\u00fchrer-Sakel D, Soares P et al. Tackling Thyroid Cancer in Europe-The Challenges and Opportunities. Healthcare (Basel) 10, 2022.","DOI":"10.3390\/healthcare10091621"},{"key":"9836_CR16","doi-asserted-by":"crossref","unstructured":"Schuster-Bruce J, Jani C, Goodall R et al. A Comparison of the Burden of Thyroid Cancer Among the European Union 15+ Countries, 1990-2019: Estimates From the Global Burden of Disease Study. JAMA Otolaryngology\u2013Head & Neck Surgery 148: 350-359, 2022.","DOI":"10.1001\/jamaoto.2021.4549"},{"key":"9836_CR17","doi-asserted-by":"crossref","unstructured":"Filetti S, Durante C, Hartl Det al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 30: 1856-1883, 2019.","DOI":"10.1093\/annonc\/mdz400"},{"key":"9836_CR18","doi-asserted-by":"crossref","unstructured":"Capdevila J, Awada A, F\u00fchrer-Sakel D, Leboulleux S, Pauwels P. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. Cancer Treatment Reviews 106, 2022.","DOI":"10.1016\/j.ctrv.2022.102380"},{"key":"9836_CR19","doi-asserted-by":"crossref","unstructured":"Romei C, Elisei R. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer. Int J Mol Sci 22, 2021.","DOI":"10.3390\/ijms22041726"},{"key":"9836_CR20","doi-asserted-by":"crossref","unstructured":"Fugazzola L, Elisei R, Fuhrer Det al. 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. Eur Thyroid J 8: 227-245, 2019.","DOI":"10.1159\/000502229"},{"key":"9836_CR21","doi-asserted-by":"crossref","unstructured":"Turchini J, Sioson L, Clarkson A et al. The Presence of Typical \"BRAFV600E-Like\" Atypia in Papillary Thyroid Carcinoma is Highly Specific for the Presence of the BRAFV600E Mutation. Endocr Pathol 34: 112-118, 2023.","DOI":"10.1007\/s12022-022-09747-9"},{"key":"9836_CR22","doi-asserted-by":"crossref","unstructured":"Rossi ED, Pantanowitz L. Typical \"BRAFV600E-Like\" Atypia in Papillary Thyroid Carcinoma: A Morphologic Sign of a Driver Mutation. Endocr Pathol 34: 265-266, 2023.","DOI":"10.1007\/s12022-023-09765-1"},{"key":"9836_CR23","doi-asserted-by":"crossref","unstructured":"Slack JC, Hollowell M, Barletta JA. Thyroid Nodules and Follicular Cell-Derived Thyroid Carcinomas in Children. Endocr Pathol 34: 165-175, 2023.","DOI":"10.1007\/s12022-023-09764-2"},{"key":"9836_CR24","doi-asserted-by":"crossref","unstructured":"Metovic J, Cabutti F, Osella-Abate S et al. Clinical and Pathological Features and Gene Expression Profiles of Clinically Aggressive Papillary Thyroid Carcinomas. Endocr Pathol 34: 298-310, 2023.","DOI":"10.1007\/s12022-023-09769-x"},{"key":"9836_CR25","doi-asserted-by":"crossref","unstructured":"Onder S, Mete O, Yilmaz I et al. DICER1 Mutations Occur in More Than One-Third of Follicular-Patterned Pediatric Papillary Thyroid Carcinomas and Correlate with a Low-Risk Disease and Female Gender Predilection. Endocr Pathol 33: 437-445, 2022.","DOI":"10.1007\/s12022-022-09736-y"},{"key":"9836_CR26","doi-asserted-by":"crossref","unstructured":"Baloch ZW, Asa SL, Barletta JA et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol 33: 27-63, 2022.","DOI":"10.1007\/s12022-022-09707-3"},{"key":"9836_CR27","doi-asserted-by":"crossref","unstructured":"Ma LX, Espin-Garcia O, Bedard PL et al. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers. Thyroid : official journal of the American Thyroid Association 32: 657-666, 2022.","DOI":"10.1089\/thy.2021.0542"},{"key":"9836_CR28","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). ed.^, eds. Thyroid Carcinoma, Version 4. 2024 - August 19, 2024 Website: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1470 (Last accessed on September 24, 2024). 2024."},{"key":"9836_CR29","doi-asserted-by":"crossref","unstructured":"Belli C, Penault-Llorca F, Ladanyi M et al. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol 32: 337-350, 2021.","DOI":"10.1016\/j.annonc.2020.11.021"},{"key":"9836_CR30","doi-asserted-by":"crossref","unstructured":"Tung N, Ricker C, Messersmith H et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol: Jco2400662, 2024.","DOI":"10.1200\/OP.24.00278"},{"key":"9836_CR31","doi-asserted-by":"crossref","unstructured":"Wells SA, Jr., Asa SL, Dralle H et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid : official journal of the American Thyroid Association 25: 567-610, 2015.","DOI":"10.1089\/thy.2014.0335"},{"key":"9836_CR32","doi-asserted-by":"crossref","unstructured":"Capezzone M, Robenshtok E, Cantara S, Castagna MG Familial non-medullary thyroid cancer: a critical review. J Endocrinol Invest 44: 943-950, 2021.","DOI":"10.1007\/s40618-020-01435-x"},{"key":"9836_CR33","doi-asserted-by":"crossref","unstructured":"Frasca F, Nucera C, Pellegriti G et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocrine-related cancer 15: 191-205, 2008.","DOI":"10.1677\/ERC-07-0212"},{"key":"9836_CR34","doi-asserted-by":"crossref","unstructured":"Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Modern Pathology 17: 1359-1363, 2004.","DOI":"10.1038\/modpathol.3800198"},{"key":"9836_CR35","doi-asserted-by":"crossref","unstructured":"Park JC, Ashok A, Liu C, Kang H. Real-World Experience of NTRK Fusion-Positive Thyroid Cancer. JCO Precis Oncol 6: e2100442, 2022.","DOI":"10.1200\/PO.21.00442"},{"key":"9836_CR36","doi-asserted-by":"crossref","unstructured":"Lee YC, Chen JY, Huang CJ, Chen HS, Yang AH, Hang JF. Detection of NTRK1\/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing. Endocr Pathol 31: 348-358, 2020.","DOI":"10.1007\/s12022-020-09648-9"},{"key":"9836_CR37","doi-asserted-by":"crossref","unstructured":"Chou A, Fraser S, Toon CW et al. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol 39: 652-659, 2015.","DOI":"10.1097\/PAS.0000000000000368"},{"key":"9836_CR38","doi-asserted-by":"crossref","unstructured":"Panebianco F, Nikitski AV, Nikiforova MN et al. Characterization of thyroid cancer driven by known and novel ALK fusions. Endocrine-related cancer 26: 803-814, 2019.","DOI":"10.1530\/ERC-19-0325"},{"key":"9836_CR39","doi-asserted-by":"crossref","unstructured":"Shih KP, Lee YC, Tsai JJ et al. Clinicopathologic Features and Cytologic Correlation of ALK-Rearranged Papillary Thyroid Carcinoma: A Series of Eight Cases. Endocr Pathol 35: 134-146, 2024.","DOI":"10.1007\/s12022-024-09808-1"},{"key":"9836_CR40","doi-asserted-by":"crossref","unstructured":"Marabelle A, Fakih M, Lopez J et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21: 1353-1365, 2020.","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"9836_CR41","unstructured":"Marabelle A, Le DT, Ascierto PA et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 38: 1-10, 2020."},{"key":"9836_CR42","doi-asserted-by":"crossref","unstructured":"Oh DY, Algazi A, Capdevila J et al. Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. Cancer 129: 1195-1204, 2023.","DOI":"10.1002\/cncr.34657"},{"key":"9836_CR43","doi-asserted-by":"crossref","unstructured":"Mehnert JM, Varga A, Brose MS et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer 19: 196, 2019.","DOI":"10.1186\/s12885-019-5380-3"},{"key":"9836_CR44","doi-asserted-by":"crossref","unstructured":"Agarwal S, Jung CK, Gaddam P et al. PD-L1 Expression and Its Modulating Factors in Anaplastic Thyroid Carcinoma: A Multi-institutional Study. Am J Surg Pathol, 2024.","DOI":"10.1097\/PAS.0000000000002284"},{"key":"9836_CR45","doi-asserted-by":"crossref","unstructured":"Zhu X, Hu C, Zhang Z et al. PD-L1 and B7-H3 are Effective Prognostic Factors and Potential Therapeutic Targets for High-Risk Thyroid Cancer. Endocr Pathol, 2024.","DOI":"10.1007\/s12022-024-09822-3"},{"key":"9836_CR46","doi-asserted-by":"crossref","unstructured":"de la Fouchardi\u00e8re C, Fugazzola L, Locati LD et al. Improved guidance is needed to optimise diagnostics and treatment of patients with thyroid cancer in Europe. Endocrine 83: 585-593, 2024.","DOI":"10.1007\/s12020-023-03610-5"},{"key":"9836_CR47","doi-asserted-by":"crossref","unstructured":"Boucher A, Ezzat S, Hotte S et al. Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer. Oral Oncol 121: 105477, 2021.","DOI":"10.1016\/j.oraloncology.2021.105477"},{"key":"9836_CR48","doi-asserted-by":"crossref","unstructured":"Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid : official journal of the American Thyroid Association 26: 1-133, 2016.","DOI":"10.1089\/thy.2015.0020"},{"key":"9836_CR49","doi-asserted-by":"crossref","unstructured":"Rahman N. Mainstreaming genetic testing of cancer predisposition genes. Clin Med (Lond) 14: 436-439, 2014.","DOI":"10.7861\/clinmedicine.14-4-436"},{"key":"9836_CR50","doi-asserted-by":"crossref","unstructured":"Filetti S, Durante C, Hartl DM et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol 33: 674-684, 2022.","DOI":"10.1016\/j.annonc.2022.04.009"},{"key":"9836_CR51","doi-asserted-by":"crossref","unstructured":"Xu B, Fuchs T, Dogan Set al. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid : official journal of the American Thyroid Association 30: 1505-1517, 2020.","DOI":"10.1089\/thy.2020.0086"},{"key":"9836_CR52","doi-asserted-by":"crossref","unstructured":"Singarayer R, Mete O, Perrier L et al. A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology. Endocr Pathol 30: 201-218, 2019.","DOI":"10.1007\/s12022-019-09585-2"},{"key":"9836_CR53","doi-asserted-by":"crossref","unstructured":"Park G, Kim TH, Lee HO et al. Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer. Endocrine-related cancer 22: 55-63, 2015.","DOI":"10.1530\/ERC-14-0467"},{"key":"9836_CR54","doi-asserted-by":"crossref","unstructured":"Yoshino T, Pentheroudakis G, Mishima S et al. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol 31: 861-872, 2020.","DOI":"10.1016\/j.annonc.2020.03.299"},{"key":"9836_CR55","doi-asserted-by":"crossref","unstructured":"Macerola E, Proietti A, Poma AM et al. Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma. Int J Mol Sci 23, 2022.","DOI":"10.3390\/ijms23137470"},{"key":"9836_CR56","doi-asserted-by":"crossref","unstructured":"Adam P, Kircher S, Sbiera I et al. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. Front Endocrinol (Lausanne) 12: 712107, 2021.","DOI":"10.3389\/fendo.2021.712107"},{"key":"9836_CR57","doi-asserted-by":"crossref","unstructured":"Dierks C, Seufert J, Aumann K et al. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid : official journal of the American Thyroid Association 31: 1076-1085, 2021.","DOI":"10.1089\/thy.2020.0322"},{"key":"9836_CR58","doi-asserted-by":"crossref","unstructured":"Luchini C, Bibeau F, Ligtenberg MJL et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 30: 1232-1243, 2019.","DOI":"10.1093\/annonc\/mdz116"},{"key":"9836_CR59","doi-asserted-by":"crossref","unstructured":"Wang C, Zhang L, Vakiani E, Shia J. Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both? Mod Pathol 35: 1515-1528, 2022.","DOI":"10.1038\/s41379-022-01109-4"},{"key":"9836_CR60","doi-asserted-by":"crossref","unstructured":"Nos\u00e9 V, Gill A, Teijeiro JMC, Perren A, Erickson L. Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes. Endocrine Pathology 33: 197-227, 2022.","DOI":"10.1007\/s12022-022-09705-5"},{"key":"9836_CR61","doi-asserted-by":"crossref","unstructured":"Peiling Yang S, Ngeow J. Familial non-medullary thyroid cancer: unraveling the genetic maze. Endocrine-related cancer 23: R577-r595, 2016.","DOI":"10.1530\/ERC-16-0067"},{"key":"9836_CR62","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Ares M, Cameselle-Garc\u00eda S, Abdulkader-Nallib I et al. Susceptibility Genes and Chromosomal Regions Associated With Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Some Pathogenetic and Diagnostic Keys. Front Endocrinol (Lausanne) 13: 829103, 2022.","DOI":"10.3389\/fendo.2022.829103"},{"key":"9836_CR63","doi-asserted-by":"crossref","unstructured":"Rivera B, Nadaf J, Fahiminiya S et al. DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis. J Clin Invest 130: 1479-1490, 2020.","DOI":"10.1172\/JCI130206"},{"key":"9836_CR64","doi-asserted-by":"crossref","unstructured":"Kamani T, Charkhchi P, Zahedi A, Akbari MR. Genetic susceptibility to hereditary non-medullary thyroid cancer. Hered Cancer Clin Pract 20: 9, 2022.","DOI":"10.1186\/s13053-022-00215-3"},{"key":"9836_CR65","doi-asserted-by":"crossref","unstructured":"Song R, Kong SY, Choi W et al. Clinical Features of Li-Fraumeni Syndrome in Korea. Cancer Res Treat 56: 334-341, 2024.","DOI":"10.4143\/crt.2023.794"},{"key":"9836_CR66","doi-asserted-by":"crossref","unstructured":"Friedman JG, Papagiannis IG. Papillary Thyroid Carcinoma, Cushing Disease, and Adrenocortical Carcinoma in a Patient with Li-Fraumeni Syndrome. AACE Clin Case Rep 10: 127-131, 2024.","DOI":"10.1016\/j.aace.2024.03.007"},{"key":"9836_CR67","doi-asserted-by":"crossref","unstructured":"Feng AL, Le A, Johnson DN, Varvares MA. Multiple simultaneous head and neck cancers in Lynch syndrome: Case report and literature review. Laryngoscope 128: 2759-2761, 2018.","DOI":"10.1002\/lary.27259"},{"key":"9836_CR68","doi-asserted-by":"crossref","unstructured":"Spinelli I, Moffa S, Fianchi F et al. Lynch Syndrome and Thyroid Nodules: A Single Center Experience. Genes (Basel) 15, 2024.","DOI":"10.3390\/genes15070859"},{"key":"9836_CR69","doi-asserted-by":"crossref","unstructured":"Baloch Z, Mete O, Asa SL. Immunohistochemical Biomarkers in Thyroid Pathology. Endocr Pathol 29: 91-112, 2018.","DOI":"10.1007\/s12022-018-9532-9"},{"key":"9836_CR70","doi-asserted-by":"crossref","unstructured":"Ott PA, Bang YJ, Piha-Paul SA et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol 37: 318-327, 2019.","DOI":"10.1200\/JCO.2018.78.2276"},{"key":"9836_CR71","doi-asserted-by":"crossref","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med 377: 2500-2501, 2017.","DOI":"10.1056\/NEJMc1713444"},{"key":"9836_CR72","doi-asserted-by":"crossref","unstructured":"Bible KC, Kebebew E, Brierley J et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid : official journal of the American Thyroid Association 31: 337-386, 2021.","DOI":"10.1089\/thy.2020.0944"},{"key":"9836_CR73","doi-asserted-by":"crossref","unstructured":"Capdevila J, Wirth LJ, Ernst T et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol 38: 2620-2627, 2020.","DOI":"10.1200\/JCO.19.02727"},{"key":"9836_CR74","doi-asserted-by":"crossref","unstructured":"Cheung CC, Barnes P, Bigras Get al. Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). Appl Immunohistochem Mol Morphol 27: 699-714, 2019.","DOI":"10.1097\/PAI.0000000000000800"},{"key":"9836_CR75","doi-asserted-by":"crossref","unstructured":"Ahn S, Kim TH, Kim SW et al. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocrine-related cancer 24: 97-106, 2017.","DOI":"10.1530\/ERC-16-0421"},{"key":"9836_CR76","unstructured":"Zeng PYF, Prokopec SD, Lai SY et al. The genomic and evolutionary landscapes of anaplastic thyroid carcinoma. Cell Rep 43: 113826, 2024."}],"updated-by":[{"DOI":"10.1007\/s12022-024-09843-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000}}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-024-09836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-024-09836-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-024-09836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T13:10:09Z","timestamp":1734613809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-024-09836-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9836"],"URL":"https:\/\/doi.org\/10.1007\/s12022-024-09836-x","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,23]]},"assertion":[{"value":"27 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to correct the citation of Table 1 in the first paragraph of section \"Constitutional (Germline) Testing in Patients Diagnosed with Non\u2011Anaplastic Follicular Cell\u2011Derived Thyroid Cancer\" to Table 2.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12022-024-09843-y","URL":"https:\/\/doi.org\/10.1007\/s12022-024-09843-y","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable for this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All authors approved the final version and publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All authors report honoraria (facilitated via Precision RxDx) from Eli Lilly Canada for participation in working group meetings related to this project.Dr. Ozgur Mete is the Editor-in-Chief of Endocrine Pathology. This article is handled by an independent senior editor as per Springer Nature\u2019s policies. Dr. Mete received honorarium for serving as an advisory board member for Bayer.Dr. Andr\u00e9e Boucher has received research support from Eisai and has been compensated for being a speaker and serving as a board member or on an advisory panel for Bayer and Eisai.Dr. Omar Abdel-Rahman has received consulting fees from Amgen, Eisai, Ipsen, Lilly, and Roche, honoraria from Bayer.Dr. Houda Bahig has received grants from AstraZeneca, Sanofi and Varian Medical Systems, as well as consulting fees from AstraZeneca and EMD Serono.Dr. Cheryl Ho received grants from AstraZeneca and Roche which were paid to her institution. She received honoraria for advisory board attendance from AbbVie, Amgen, AstraZeneca, Bayer, BMS, Janssen, Jazz, Merck, Novartis, Pfizer, Roche, and Sanofi.Dr. Kasmintan A. Schrader has a consulting and advisory relationship with and has received honoraria from AstraZeneca Canada and Pfizer and research funding from AstraZeneca Canada and Merck.Dr. Eric Winquist received grants from Eli Lilly, Merck, and Novartis which were paid to his institution. He received consulting fees for advisory boards from Bayer, BMS, Eisai, EMD Serono, Merck, and Roche; honoraria from EMD Serono and support for attending meetings from Eisai.Dr. Jonn Wu served as an Executive board member, International Society of Oral Oncology, from 2019 to 2023.Dr. Shereen Ezzat has served as advisory board member\/consultant for Bayer, Eisai, Eli Lilly, Ipsen, Novartis, Medunik Canada, Merck, Pfizer, and Recordati Rare Diseases.Dr. Nicole Chau has received research funding from BeiGene, BMS, ERASCA, Merck, and Roche which were paid to her institution. She received consulting fees for advisory boards from Bayer, BMS, Eisai, Eli Lilly, EMD Serono, Ipsen, Merck, Novartis, Pfizer, and Roche.Dr. Olfat Kamel Hasan, Dr. Bernard Lemieux, and Dr. Ralph Wong have no conflicts of interest to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}